Page last updated: 2024-09-04

cyc 682 and Lung Neoplasms

cyc 682 has been researched along with Lung Neoplasms in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Galmarini, CM	1
Baker, SD; Carducci, MA; Dees, EC; Donehower, R; Gilbert, J	1

Trials

1 trial(s) available for cyc 682 and Lung Neoplasms

Article	Year
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Investigational new drugs, 2006, Volume: 24, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; Breast Neoplasms; Colorectal Neoplasms; Cytosine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prodrugs; Treatment Failure; Treatment Outcome	2006

Article

Year

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.

Investigational new drugs, 2006, Volume: 24, Issue:6

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; Breast Neoplasms; Colorectal Neoplasms; Cytosine; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prodrugs; Treatment Failure; Treatment Outcome

2006

Other Studies

1 other study(ies) available for cyc 682 and Lung Neoplasms

Article	Year
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6 Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cytosine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Patents as Topic	2006

Article

Year

Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.

Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6

Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Cytosine; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Patents as Topic

2006